Inopin

Correct acute hypotension, unresponsive to adequate fluid vol replacement. Cardiogenic shock caused by MI, trauma, endotoxic septicemia, open heart surgery, renal failure. Improve cardiac output during cardiac decompensation in CHF. Short-term management of severe CHF refractory to digitalis & diuretics.

IV infusion Initially 2-5 mcg/kg/min then gradually increase to 5-10 mcg/kg/min according to patient's BP, cardiac & urine output. Seriously ill patients Up to 20-50 mcg/kg/min.

Hypersensitivity to sulfites. Pheochromocytoma; uncorrected tachyarrhythmias; ventricular fibrillation.

Sulfite sensitivity more frequently in asthmatic than in non-asthmatic people. Not recommended to administer into umbilical arterial catheter. Discontinue use & administer a more potent vasoconstrictor eg, norepinephrine if hypotension persist. Discontinue use or decrease rate of infusion if change in skin color or temp occurs. Ensure hypovolemia is fully corrected (if possible w/ either whole blood or plasma indicated) prior to treatment. Correct hypoxia, hypercapnia & acidosis prior to & while on treatment. Reduce dose if an increased number of ectopic beats are observed. Carefully observe patient for further evidence of predominant vasoconstrictor activity. Possible extravasation. Closely monitor patients w/ history of occlusive vascular disease (eg, atherosclerosis, arterial embolism, Raynaud disease, cold injury eg, frostbite, diabetic endarteritis, Buerger disease) for any changes in skin color or temp in extremities. Monitor central venous pressure or left ventricular filling pressure. Rapidly increase infusion rate until adequate BP is obtained. Continuously monitor infusion site for free flow. Immediately infiltrate area w/ diluted phentolamine (5-10 mg in 10-15 mL saline) w/ fine hypodermic needle if extravasation occurs. Gradually decrease dose while expanding blood vol w/ IV fluids. Pregnancy & lactation. Paed.

Angina pectoris, atrial fibrillation, bradycardia, ectopic beats, HTN, hypotension, palpitations, tachycardia, vasoconstriction, ventricular arrhythmia & conduction abnormality, widened QRS complex on ECG; anxiety, headache; gangrene in high dose, piloerection; increased serum glucose (usually not above normal limits); nausea, vomiting; azotemia; increased IOP, mydriasis; polyuria; dyspnea; tissue necrosis.

Prolonged & intensified effects w/ MAOIs. Antagonized peripheral vasoconstriction w/ α-adrenergic blocking agents. Halothane (or other halogenated hydrocarbon) or cyclopropane anesth; phenytoin; vasopressors or vasoconstrictors (eg, ergonovine).

Cardiac Drugs

C01CA04 - dopamine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of hypotension.

D